Cargando…
A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma
Lung squamous cell carcinoma (LUSC) comprises 20–30% of all lung cancers. Immunotherapy has significantly improved the prognosis of LUSC patients; however, only a small subset of patients responds to the treatment. Therefore, we aimed to develop a novel multi-gene signature associated with the immun...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372044/ https://www.ncbi.nlm.nih.gov/pubmed/35953696 http://dx.doi.org/10.1038/s41598-022-17735-6 |